Barclays’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-21
| Closed | -$96 | – | 5202 |
|
|
2025
Q3 | $96 | Buy |
+21
| New | +$62 | ﹤0.01% | 5277 |
|
|
2025
Q2 | – | Sell |
-29,510
| Closed | -$129K | – | 5218 |
|
|
2025
Q1 | $129K | Sell |
29,510
-10,377
| -26% | -$46.8K | ﹤0.01% | 4299 |
|
|
2024
Q4 | $186K | Buy |
39,887
+4,055
| +11% | +$27.3K | ﹤0.01% | 4348 |
|
|
2024
Q3 | $252K | Buy |
35,832
+19,965
| +126% | +$145K | ﹤0.01% | 4181 |
|
|
2024
Q2 | $109K | Sell |
15,867
-37,391
| -70% | -$348K | ﹤0.01% | 3866 |
|
|
2024
Q1 | $753K | Buy |
+53,258
| New | +$810K | ﹤0.01% | 3332 |
|
|
2022
Q2 | – | Sell |
-1,410
| Closed | -$18K | – | 4990 |
|
|
2022
Q1 | $18K | Sell |
1,410
-9,135
| -87% | -$134K | ﹤0.01% | 4467 |
|
|
2021
Q4 | $185K | Buy |
10,545
+5,614
| +114% | +$112K | ﹤0.01% | 3592 |
|
|
2021
Q3 | $107K | Sell |
4,931
-968
| -16% | -$24.7K | ﹤0.01% | 3878 |
|
|
2021
Q2 | $207K | Sell |
5,899
-12,026
| -67% | -$648K | ﹤0.01% | 3537 |
|
|
2021
Q1 | $1.77M | Sell |
17,925
-11,553
| -39% | -$1.39M | ﹤0.01% | 2387 |
|
|
2020
Q4 | $3.19M | Sell |
29,478
-10,125
| -26% | -$1.25M | ﹤0.01% | 1859 |
|
|
2020
Q3 | $4.08M | Buy |
39,603
+11,321
| +40% | +$1.7M | ﹤0.01% | 1530 |
|
|
2020
Q2 | $5.91M | Buy |
28,282
+1,414
| +5% | +$250K | ﹤0.01% | 1250 |
|
|
2020
Q1 | $2.63M | Sell |
26,868
-19,456
| -42% | -$2.27M | ﹤0.01% | 2029 |
|
|
2019
Q4 | $5.34M | Buy |
46,324
+41,814
| +927% | +$3.69M | ﹤0.01% | 1936 |
|
|
2019
Q3 | $246K | Sell |
4,510
-1,478
| -25% | -$167K | ﹤0.01% | 4817 |
|
|
2019
Q2 | $711K | Buy |
5,988
+1,079
| +22% | +$89.3K | ﹤0.01% | 4019 |
|
|
2019
Q1 | $258K | Buy |
4,909
+3,123
| +175% | +$126K | ﹤0.01% | 4637 |
|
|
2018
Q4 | $56K | Sell |
1,786
-5,128
| -74% | -$209K | ﹤0.01% | 5412 |
|
|
2018
Q3 | $418K | Buy |
6,914
+4,698
| +212% | +$264K | ﹤0.01% | 4423 |
|
|
2018
Q2 | $117K | Sell |
2,216
-7,372
| -77% | -$443K | ﹤0.01% | 5129 |
|
|
2018
Q1 | $556K | Buy |
9,588
+6,143
| +178% | +$382K | ﹤0.01% | 3863 |
|
|
2017
Q4 | $120K | Buy |
3,445
+3,000
| +674% | +$98.7K | ﹤0.01% | 5098 |
|
|
2017
Q3 | $16K | Sell |
445
-10,953
| -96% | -$304K | ﹤0.01% | 5890 |
|
|
2017
Q2 | $285K | Buy |
11,398
+10,068
| +757% | +$275K | ﹤0.01% | 4054 |
|
|
2017
Q1 | $35K | Buy |
1,330
+352
| +36% | +$10K | ﹤0.01% | 5529 |
|
|
2016
Q4 | $28K | Buy |
+978
| New | +$32K | ﹤0.01% | 5461 |
|
|
2016
Q3 | – | Sell |
-50
| Closed | -$1.9K | – | 6578 |
|
|
2016
Q2 | $1K | Buy |
50
+33
| +194% | +$1.49K | ﹤0.01% | 6051 |
|
|
2016
Q1 | $1K | Sell |
17
-24
| -59% | -$1.34K | ﹤0.01% | 5940 |
|
|
2015
Q4 | $2K | Sell |
41
-712
| -95% | -$62.6K | ﹤0.01% | 5732 |
|
|
2015
Q3 | $60K | Sell |
753
-36
| -5% | -$4.6K | ﹤0.01% | 4917 |
|
|
2015
Q2 | $126K | Sell |
789
-1,163
| -60% | -$392K | ﹤0.01% | 4486 |
|
|
2015
Q1 | $781K | Buy |
1,952
+1,903
| +3,884% | +$804K | ﹤0.01% | 3192 |
|
|
2014
Q4 | $26K | Buy |
+49
| New | +$18.9K | ﹤0.01% | 6156 |
|
Barclays's ADVM Position: Q4 2025 in Review
Barclays sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 21 shares — an estimated $96 sold.
Barclays first reported a position in ADVM in Q4 2014 and held it in 35 quarters. The position peaked at $5.91M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Barclays reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Barclays sold 21 Adverum Biotechnologies shares in Q4 2025, an estimated $96.
- Barclays first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 35 quarters.
- Barclays's Adverum Biotechnologies position peaked at $5.91M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.